Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell analysis: is the sector blowing name bubbles?

March 29, 2017 9:08pm

What's frustrating is investor not knowing if yesterday or even today - is an indication that cell therapy’s share price will stay on track …

Pre-open indications: five (5) hits and 0 miss

Out and about: Pluristem (PSTI) Yaky Yanay, the current CFO, President and COO was appointed co-CEO

I answer one question, in which company should investors put, keep and commit their money

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

Henry’omics:

From the pre-open’s investor’s letter title,” the factors relating to value destruction … A is for algorithms to take over stock picking while we experience our own algorithms/server “glitch”

Reiterating, “As money managers seek to let the machines manage investor’s funds, some call it the democratization of information and I believe our sector is in deep trouble.”

I have MY doubts on their dependence – as they don’t respect the concept of human input and analysis …

Cell therapy stocks traded mostly higher Wednesday, with most of the “usual suspects” seeing movement.

Stocks are on track to record a not seen (recently) – a record of five (5) up days.

But, I am in a wait-and-see mode to sell if this level of upside will continue

Pre-open indications: five (5) hits and 0 miss

Asterias Biotherapeutics (NYSEMKT: AST) closed down -$0.10 – hit;
Athersys (ATHX) closed up +$0.26 – hit;
Regenxbio (RGNX) closed down -$0.55 – hit;
Cellectis (CLLS) closed down -$0.04 – hit;
Opexa (OPXA) closed down - $0.0438 – hit;

What analytics were there today and why it was important in today’s sector outcomes?

The DOW closed down -42.18 or -0.20% to 20,659.32 while the NASDAQ closed up +22.41 or +0.38% to 5897.55 …

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 11.4 after Tuesday’s 11.5 following Monday’s 13.3

…The iShares Russell 2000 (IWM) was down -0.34% at the pre-open was and closed UP +0.32%;

… The iShares NASDAQ Biotechnology (IBB) was up +0.41% at the pre-open and closed DOWN -0.83%.

The advance/decline line scenario of 43 SCGT & RT covered companies:

· The opening bell was positive with an A/DL of 27/13 and 3 flats;

· The mid-day continued positive with an A/DL of 32/10 and 1 flat;

· The close was positive with an A/DL of 24/14 and 5 flats;

… Decliners ranged from -0.11% <BLUE> to -6.67% <IMUC> in 14 equities;

… Gainers ranged from +0.21% <OSIR> to +22.03% <ATHX> in 24 equities;

Out and about:

Pluristem’s (PSTI) Board of Directors of the registrant appointed Yaky Yanay, the current Chief Financial Officer, President and Chief Operating Officer, as co-Chief Executive Officer along with Mr. Zami Aberman, the registrant's other Co-CEO and Chairman.

Mr. Yanay will remain as the registrant's President. In conjunction with his appointment as Co-CEO, Mr. Yanay was relieved of his duties as Chief Financial Officer and Chief Operating Officer of the registrant.

In addition, on March 29, 2017, the Board of Directors of the registrant appointed Erez Egozi to serve as the registrant's Chief Financial Officer and Treasurer. Prior to his appointment as Chief Financial Officer, Mr. Egozi served as the registrant's Vice President of Finance from March 2015 until March 2017.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.